Peptide Science Cobar

Peptide Science Cobar: Pioneering Mitochondrial-Derived Therapies for Age-Related Diseases

Introduction of Peptide Science Cobar

In the evolving landscape of biotechnology, few areas hold as much promise for extending human healthspan as the study of mitochondrial-derived peptides (MDPs). At the forefront of this emerging field is CohBar, a clinical-stage biotechnology company whose name—often misheard or misspelled as “Cobar”—has become synonymous with innovative peptide science. Founded on the groundbreaking discovery that the mitochondrial genome encodes biologically active peptides with profound effects on metabolism and cellular health, Peptide Science Cobar represents a unique convergence of longevity research, peptide chemistry, and therapeutic development.

The Origin and Mission of CohBar

CohBar was founded in 2009 by Dr. Nir Barzilai and Dr. Pinchas Cohen, researchers at the Albert Einstein College of Medicine in New York City. Their journey began with the Longevity Genes Project, an ongoing study initiated in 1998 to identify genes that promote long life. Through this research, they made a remarkable discovery: centenarians and their offspring exhibit significantly higher levels of a peptide called humanin in their blood compared to individuals with average life expectancy. These same individuals also enjoyed extraordinarily disease-free lives, suggesting a direct connection between this mitochondrial peptide and healthy aging.

The company’s name, CohBar, reflects its dual commitment to collaboration (“Co”) and the pioneering work of its founders (“hBar” referencing Barzilai). Headquartered in Menlo Park, California, CohBar has positioned itself as a first mover in exploring the mitochondrial genome to identify MDPs with the potential to become transformative medicines.

The Science of Mitochondrial-Derived Peptides

Mitochondria: More Than Cellular Powerhouses

Traditionally, mitochondria have been understood as the “powerhouses of the cell,” responsible for producing ATP through oxidative phosphorylation. However, Peptide Science Cobar founders recognized that mitochondria serve an additional critical function: they encode biologically active peptides that regulate metabolism, cell death, and systemic biological pathways.

The mitochondrial genome (mtDNA) is a small, circular DNA molecule inherited exclusively from the mother. For decades, it was believed to encode only 13 proteins essential for energy production. CohBar’s pioneering research revealed that mtDNA also contains sequences encoding numerous small peptides—now known as mitochondrial-derived peptides (MDPs)—that have been conserved through human evolution. These peptides are secreted by cells and exert effects far beyond the mitochondria themselves, influencing critical processes throughout the body.

The MDP Discovery Platform

Peptide Science Cobar has developed a proprietary technology platform for systematically discovering, characterizing, optimizing, patenting, and producing MDPs as therapeutic agents. The company’s research efforts have historically focused on utilizing this platform to identify, assess, and optimize novel analogs of native peptides found in the mitochondrial genome.

To date, CohBar and its founders have discovered more than 50 biologically active MDPs. These peptides demonstrate a remarkable range of potential therapeutic effects in preclinical disease models, including metabolic regulation, neuroprotection, cytoprotection, and anti-inflammatory activity. The company’s intellectual property portfolio includes six issued patents and approximately 30 pending patent applications, providing broad protection for its MDP compositions and methods of use.

Major Therapeutic Candidates

MOTS-c: The Metabolic Regulator

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is an MDP discovered in 2012 by CohBar’s founders and their academic collaborators. Laboratory and rodent studies indicate that MOTS-c plays a significant role in the regulation of metabolism. A MOTS-c analog has demonstrated therapeutic potential for Type 2 diabetes mellitus, obesity, fatty liver disease, and certain cancers.

The mechanism of action involves sensitization of the insulin receptor, effectively improving the body’s response to insulin and normalizing metabolic function. This positions MOTS-c analogs as potential treatments for the metabolic dysfunction underlying many age-related diseases.

CB4211: Leading Clinical Candidate

CB4211 represents CohBar’s most advanced therapeutic candidate, an optimized analog derived from the MOTS-c program. In July 2018, CohBar achieved a significant milestone when CB4211 entered clinical trials for the first time, marking the company’s transition from a research-stage to a clinical-stage biotechnology company.

CB4211 targets non-alcoholic steatohepatitis (NASH) and obesity, two increasingly prevalent conditions associated with cardiovascular disease and cancer. The therapeutic approach involves regulation of fat metabolism, reduction of liver fat, and normalization of body weight. With no approved drugs currently available for NASH and a U.S. market estimated at up to $40 billion annually, the potential impact is substantial.

SHLP Family: Expanding the Pipeline

CohBar has also discovered several other MDPs with properties related to humanin, referred to as small humanin-like peptides (SHLPs). SHLP6 and SHLP2 are being evaluated for their potential to treat a wide range of age-related diseases, including cancer, Type 2 diabetes, and Alzheimer’s disease. These compounds represent promising opportunities for both internal development and strategic partnerships.

Clinical Progress and Challenges

Navigating the Clinical Pathway

CohBar’s clinical journey has not been without obstacles. In November 2018, the company announced a temporary suspension of the CB4211 Phase 1a/1b study to address mild injection site reactions. These reactions, which appeared as painless bumps under the skin, were determined not to be a significant safety issue but required formulation adjustments. The company submitted its data and an amended clinical plan to the FDA, demonstrating its commitment to rigorous scientific standards.

Financial Position and Strategy

As a clinical-stage biotechnology company, CohBar has financed its operations primarily through equity securities offerings, including an initial public offering and private placements. The company has not yet generated revenue from product sales and continues to operate at a loss, consistent with the development-stage nature of its business.

CohBar’s strategy emphasizes building a multi-product company through internal development and strategic partnerships with larger pharmaceutical organizations. This approach leverages the company’s first-mover advantage in MDP-based therapeutics while sharing the risks and costs of late-stage development.

The Future of Peptide Science at CohBar

Expanding the Therapeutic Frontier

The potential applications of MDPs extend far beyond metabolic diseases. Preclinical research suggests these peptides may address cardiovascular disorders, neurodegenerative conditions, and even certain cancers. As CohBar continues to explore its library of over 50 peptides, new therapeutic opportunities are likely to emerge.

Scientific Validation and Industry Recognition

CohBar’s addition to the Russell Index in June 2018 and its record-level financing demonstrated growing institutional recognition of the company’s potential. The depth of the company’s scientific expertise, combined with its expanding intellectual property portfolio, positions it to sustain its competitive advantage in this emerging field.

Conclusion

CohBar—often encountered as “Peptide Science Cobar” in discussions of mitochondrial therapeutics—represents a compelling chapter in the story of peptide science and longevity research. By unlocking the therapeutic potential of mitochondrial-derived peptides, the company has opened a new frontier in the treatment of age-related diseases. While significant challenges remain on the path to commercialization, the scientific foundation is solid, the therapeutic potential is vast, and the vision of extending healthy human lifespan through mitochondrial medicine continues to drive innovation forward.

As our understanding of mitochondrial biology deepens and clinical programs advance, CohBar’s pioneering work may ultimately transform how we approach some of the most pressing health challenges of our aging population. The journey from fundamental discovery to therapeutic reality is long, but the promise of MDP-based medicines offers hope for a future where aging is accompanied not by disease, but by sustained health and vitality.